Work

Abstract 5783: HY809382, a PRC2 degrader with best-in-class properties, demonstrates efficacy across multiple tumors and overcomes EZH2 inhibitor clinical resistance caused by EZH2 genetic mutations

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-5783

Authors: Xin Li, Weixing Zhu, Ruwei Wang, Zengrong Li, Liming Zhang, Lei Chen, Sai Yang, Feng Xu, Qian Ma, Huangtao Jin, Xiaotian Huang, Ting Zhang, Xing Yu, Ming Weng, Xiaoxiao Wang, Xiaohong Hou, Manli Hu, Tingting Dai, Ruowen Zhang, Juan Du

Institution: Yangtze River Pharmaceutical Group (China)

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148847764

Cites:

Cited by:

Related to: